Drug combo is first to prolong ketamine’s anti-suicide effects
Research
New research indicates that low-dose buprenorphine can extend ketamine’s temporary anti-suicide effects by at least four weeks.
Trial leads to FDA approval of drug for rare, deadly blood cancer
Research
Fewer than half of patients with a rare blood cancer subtype survive beyond a year. A Stanford Medicine-led trial has led to FDA approval of a new treatment that holds the promise of improving survival rates.
AI tackles antibiotic resistance
Research
Stanford Medicine researchers devise a new artificial intelligence model, SyntheMol, which creates recipes for chemists to synthesize the drugs in the lab.